Compounds > piperacillin
Page last updated: 2024-08-23

piperacillin and E coli Infections

piperacillin has been researched along with E coli Infections in 96 studies

Research

Studies (96)

TimeframeStudies, this research(%)All Research%
pre-19903 (3.13)18.7374
1990's7 (7.29)18.2507
2000's27 (28.13)29.6817
2010's49 (51.04)24.3611
2020's10 (10.42)2.80

Authors

AuthorsStudies
Abe, T; Ado, M; Agarwal, A; Dos Santos, O; Francisco, G; Gu, Y; Knox, JR; Kumagai, T; Li, Z; Lin, YI; Mansour, TS; Petersen, PJ; Shlaes, DM; Sum, FW; Tsuyoshi, T; Ushirogochi, H; Venkatesan, AM; Weiss, WJ; Yamamura, I; Yang, Y1
Caniça, M; Ferreira, E; Leitão, J; Manageiro, V; Mendonça, N1
Baudry, PJ; DeCorby, M; Hoban, DJ; Mataseje, L; Mulvey, MR; Nichol, K; Zhanel, GG1
Jarlier, V; Mayer, C; Petrella, S; Renard, M; Sougakoff, W; Ziental-Gelus, N1
Cattoir, V; Nordmann, P; Poirel, L1
Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S1
Cars, O; Löwdin, E; Melhus, A; Tängdén, T1
Almind, SR; Andreasen, MR; Frimodt-Møller, N; Hansen, KH; Hertz, FB; Jelsbak, L; Nielsen, KL; Schønning, K1
Bauer, MJ; Flora, MS; Forde, BM; Habib, ZH; Harris, P; Islam, K; Roberts, JA; Shirin, T; Sime, FB; Wallis, SC1
Al Atbee, MYN; Jalil, MB1
Deligios, M; Fiamma, M; Paglietti, B; Rubino, S; Sacarlal, J; Santona, A; Simbine, SE; Sumbana, JJ; Taviani, E; Zimba, T1
Cottrell, K; Harris, PNA; Heffernan, AJ; Lipman, J; Naicker, S; Roberts, JA; Sime, FB; Sumi, CD; Wallis, SC1
Dong, L; Feng, J; Geng, H; Gu, S; He, C; Hou, G; Ji, T; Kang, W; Lai, J; Li, Y; Li, Z; Pang, D; Wang, Y; Zhao, L; Zhu, X; Zhu, Y1
Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I1
Al-Dahmoshi, HOM; Ben Amara, I; Eleroui, M; Mukheef, SA1
Bahrs, C; Bartonickova, L; Burgmann, H; Hagel, S; Paulussen, E; Pletz, MW; Schneider, L; Starzengruber, P; Tobudic, S1
Adams, ER; Bulgasim, I; Corless, C; Edwards, T; Fraser, AJ; Howard, A; Hubbard, ATM; Mason, J; Parry, CM; Roberts, AP; Roberts, P; van Aartsen, J1
Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y1
Ashraf, T; Darwish, D; Ghazawi, A; Mohsin, J; Pál, T; Petersen, JE; Sonnevend, A1
Bailoor, K; Chen, T1
Choi, JK; Joo, EJ; Ko, JH; Lee, NR; Moon, SY; Park, DA; Peck, KR1
Bansal, N; Gopalakrishnan, R; Kumar D, S; Nambi, PS; Ramasubramanian, V; Sukhwani, KS1
Bergen, PJ; Bulitta, JB; Kirkpatrick, CMJ; Landersdorfer, CB; Lipman, J; McGregor, MJ; Millen, N; Paterson, DL; Roberts, JA; Sime, FB1
Adam, T; Bachmann, F; Budde, K; Friedersdorff, F; Liefeldt, L; Slowinski, T; Waiser, J1
Al Khamis, M; Alenazi, TH; Arabi, Y; Athan, E; Baker, P; Bassetti, M; Beatson, SA; Bhally, H; Boyles, TH; Crowe, A; Daneman, N; Falcone, M; Griffin, P; Harris, PNA; Harris-Brown, T; Ingram, P; Iredell, J; Kanj, S; Lee, TH; Looke, D; Lorenc, P; Lye, DC; Mendelson, M; Miyakis, S; Mo, Y; Paterson, DL; Peleg, AY; Righi, E; Roberts, L; Rogers, BA; Tambyah, PA; Walls, G; Yilmaz, M; Zikri, A1
Bernhardt, M; Boschert, EN; Dubin, JR; Lauer, MF1
Jacqz-Aigrain, E; Leroux, S; Magréault, S; Storme, T; Touati, J1
Docobo-Pérez, F; Domínguez-Herrera, J; Egea, P; López-Cerero, L; López-Rojas, R; Pachón, J; Pascual, A; Rodríguez-Baño, J1
Choi, EH; Lee, HJ; Lee, J; Oh, CE1
López-Cerero, L; Muniain, MA; Pascual, Á; Retamar, P; Rodríguez-Baño, J1
Kumar, A; Shahi, SK; Singh, VK1
Belghiti, J; Bert, F; Dondero, F; Durand, F; Larroque, B; Moreau, R; Nicolas-Chanoine, MH; Paugam-Burtz, C1
Doi, Y; Qureshi, ZA1
Coleman, K; Girard, AM; Lavallade, L; Levasseur, P; Miossec, C; Pace, J1
Bae, EY; Cho, B; Chung, NG; Han, SB; Jeong, DC; Jung, SW; Kang, JH; Kim, HK; Lee, DG; Lee, JW; Park, YJ1
Athan, E; Baker, P; Harris, PN; Harris-Brown, T; Ingram, PR; Iredell, J; Lipman, J; McBryde, ES; Miyakis, S; Paterson, DL; Paul, SK; Peleg, AY; Roberts, JA; Rogers, BA; Stewardson, AJ1
Hong, MT; Seifert, CF1
Davin-Regli, A; Franceschi, C; Pagès, JM; Pinet, E; Zambardi, G1
Bruna-Romero, O; da Glória de Souza, D; de Andrade, JP; de Carvalho, MA; de Macêdo Farias, L; dos Santos, KV; Ferreira, JF1
Arakawa, Y; Fujita, A; Jin, W; Kimura, K; Mikamo, H; Suematsu, H; Wachino, J; Yamada, K; Yamagishi, Y; Yokoyama, S1
Aldakhil, LO; Alobaid, AS; Alsahabi, JA1
Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH1
Becker, K; Bletz, S; Böking, T; Harmsen, D; Kipp, F; Mellmann, A; Prior, K; Schultes, A1
Monogue, ML; Nicolau, DP1
Beerle, C; Breitenstein, S; Gelpke, H; Staerkle, RF1
Aslanzadeh, J; Brecher, SM; Monogue, ML; Nicolau, DP; Tanner, LK1
Kim, JH; Kim, MJ; Sohn, JW; Yang, KS; Yoon, YK1
Church, DL; Gregson, DB; Laupland, KB; Le, P; Pitout, JD1
Bechtold, A; Gastmeier, P; Lapatschek, M; Meyer, E; Schwab, F; Schwarzkopf, G1
Docobo, F; Hernández, JR; López-Cerero, L; Morillo, C; Pachón, J; Pascual, A; Picón, E; Rodríguez-Baño, J1
Cortés, C; Giménez, L; Pueyo, A; Ramos, A1
Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC1
Calcinari, A; Casteletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Guerrieri, M; Kamysz, E; Kamysz, W; Orlando, F; Rimini, M; Silvestri, C; Tocchini, M1
Barros-Garcia, P; Molina-Infante, J; Perez-Gallardo, B1
Bonnet, R; Delmas, J; Gibold, L; Krebs, M; Mirande, C; Robin, F1
Buffé, C; Dalla Costa, T; de Araujo, BV; Diniz, A; Palma, EC1
Bonomo, RA; Perez, F1
Navarro, MD; Pascual, Á; Picón, E; Retamar, P; Rodríguez-Baño, J1
Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR1
Hanson, ND; Kurpiel, PM1
Homann, C; Knudsen, JD; Moser, C; Novovic, S; Olsen, H; Semb, S1
Anderson, DJ; Bennett, KM; Dotson, TL; Sarraf-Yazdi, S; Sharpe, M; Vaslef, SN1
Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Wu, HH1
Bilker, WB; Edelstein, PH; Han, JH; Kasahara, K; Lautenbach, E1
Creely, D; Dunne, WM; Gayral, JP; Peyret, M; Shortridge, D; Shubert, C; van Belkum, A; Zambardi, G1
Gesser, RM; McCarroll, K; Teppler, H; Woods, GL1
Cirioni, O; D'Amato, G; Del Prete, MS; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Riva, A; Saba, V; Scalise, G; Silvestri, C1
Fung, CP; Hsueh, PR; Lan, CK; Lau, YT; Su, CC; Wong, WW; Yeung, JY; Young, GT1
Cirioni, O; D'Amato, G; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Sisti, V1
Cirioni, O; D'Amato, G; Del Prete, MS; Ghiselli, R; Giacometti, A; Kamysz, W; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Viticchi, C; łLukasiak, J1
Derendorf, H; Liu, Q; Rand, K1
Cirioni, O; D'Amato, G; Ghiselli, R; Giacometti, A; Kamysz, W; Lukasiak, J; Mocchegiani, F; Naldoski, P; Orlando, F; Saba, V; Scalise, G; Silvestri, C; Sisti, V1
Cirioni, O; D'Amato, G; Ghiselli, R; Giacometti, A; Kamysz, W; Mocchegiani, F; Orlando, F; Rocchi, M; Saba, V; Scalise, G; Silvestri, C; Łukasiak, J1
Andersen, NF; Møller, J; Peterslund, NA1
Bordigoni, P; Chastagner, P; Fouyssac, F; Mansuy, L; Salmon, A; Schmitt, C1
Asperger, W; Chan, CY; Dela Pena, AS; DiNubile, MJ; Giezek, H; Kafka, R; Köckerling, F; Raz, R; Shivaprakash, M; Vrijens, F; Warren, B1
Bergnach, C; Cirioni, O; Ghiselli, R; Giacometti, A; Licci, A; Mocchegiani, F; Orlando, F; Rocchi, M; Saba, V; Scalise, G; Silvestri, C; Skerlavaj, B; Zanetti, M1
de Cueto, M; Hernández, JR; Muniain, MA; Navarro, MD; Pascual, A; Ríos, MJ; Rodríguez-Baño, J; Romero, L1
Harada, AS; Lau, W1
Agarwal, N; Agarwal, S; Arya, SC; Solanki, BS1
Apolônio, ACM; Carvalho, MAR; Coutinho, SC; Diniz, CG; Farias, LM; Martins, WA; Nicoli, JR; Santos, KVD1
Bai, YL; Chen, BY; Chu, YZ; Li, JB; Li, LY; Wan, JH; Wang, Q; Wang, X; Zhang, JP; Zhao, ZM1
Abbruzzetti, A; Cirioni, O; Di Matteo, F; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G; Silvestri, C1
Barnaud, G; Chevrel, G; Dreyfuss, D; Eveillard, M; Meybeck, A; Mounier, R; Ricard, JD1
George, CR; Guinness, MD1
Duncanson, FP; Norden, CW; Talan, DA; Tan, JS; Wishnow, RM1
Shinagawa, N1
Fernández-Roblas, R; Gadea, I; García-Corbeira, P; Ponte, C; Soriano, F1
Abe, S; Ikeda, T; Suegara, N; Yamaguchi, H1
Mohammedi, I; Tigaud, S; Tournadre, JP1
Chen, Y; Gao, L; Hou, F; Li, J1
Berry, V; Mizen, L; Woodnutt, G1
Gunderson, D; Kennedy, SL; Kern, W; Sachdeva, M; Sande, ER; Täuber, MG1
Hashimoto, I; Maezawa, I; Matsushita, T; Nakamura, T; Ohshima, S; Okuno, S; Sawada, Y; Yamaguchi, T1
Aldridge, KE; Derks, FW; Marier, RL; Martin, DH; Sanders, CV1

Reviews

3 review(s) available for piperacillin and E coli Infections

ArticleYear
Escherichia coli sequence type 131: epidemiology and challenges in treatment.
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:5

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Cystitis; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; United States

2014
[Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].
    Medecine et maladies infectieuses, 2005, Volume: 35, Issue:6

    Topics: Adolescent; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Child; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Escherichia coli Infections; Female; Fever; Fever of Unknown Origin; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Infant; Male; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Retrospective Studies; Treatment Outcome; Urinary Tract Infections

2005
[The pathophysiology and treatment of severe intra-abdominal abscess].
    Nihon Geka Gakkai zasshi, 1996, Volume: 97, Issue:12

    Topics: Abdominal Abscess; Cefazolin; Cephalosporins; Enterococcus faecalis; Escherichia coli Infections; Gram-Positive Bacterial Infections; Humans; Intestines; Penicillins; Peritoneal Diseases; Piperacillin

1996

Trials

7 trial(s) available for piperacillin and E coli Infections

ArticleYear
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    BMC infectious diseases, 2017, 06-07, Volume: 17, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections

2017
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    JAMA, 2018, 09-11, Volume: 320, Issue:10

    Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Cause of Death; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins

2018
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
    Trials, 2015, Jan-27, Volume: 16

    Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Clinical Protocols; Drug Resistance, Microbial; Escherichia coli Infections; Humans; Klebsiella Infections; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sample Size; Thienamycins

2015
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 51, Issue:5

    Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections

2003
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2006, Volume: 10, Issue:4

    Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Diarrhea; Ertapenem; Escherichia coli Infections; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome

2006
Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
    Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:8

    Topics: Bacteroides Infections; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Skin Diseases, Bacterial; Staphylococcal Skin Infections; Staphylococcus aureus; Tazobactam; Ticarcillin

1993
A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Chinese medical journal, 1998, Volume: 111, Issue:11

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Clavulanic Acid; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli Infections; Female; Humans; Male; Penicillanic Acid; Penicillins; Piperacillin; Pneumonia; Respiratory Tract Infections; Tazobactam; Ticarcillin; Urinary Tract Infections

1998

Other Studies

86 other study(ies) available for piperacillin and E coli Infections

ArticleYear
Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.
    Journal of medicinal chemistry, 2006, Jul-27, Volume: 49, Issue:15

    Topics: Aldehydes; Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Enterobacter aerogenes; Enterobacteriaceae Infections; Escherichia coli Infections; Gram-Negative Bacteria; Heterocyclic Compounds, 2-Ring; Imidazoles; Mice; Microbial Sensitivity Tests; Models, Molecular; Pyrazoles; Stereoisomerism; Structure-Activity Relationship; Thiazepines; Thiophenes

2006
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:6

    Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Middle Aged; Portugal

2007
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5

    Topics: Bacterial Proteins; beta-Lactamases; Canada; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Gentamicins; Humans; Intensive Care Units; Microbial Sensitivity Tests

2008
Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Aged; Base Sequence; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Catalytic Domain; Cephalosporin Resistance; Crystallography, X-Ray; DNA Primers; DNA, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; France; Genes, Bacterial; Humans; Imipenem; Kinetics; Male; Models, Molecular; Mutation

2008
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids

2008
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6

    Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors

2010
Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Child; Child, Preschool; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Sweden; Travel; White People; Young Adult

2010
Efficacy of piperacillin-tazobactam and cefotaxime against Escherichia coli hyperproducing TEM-1 in a mouse peritonitis infection model.
    International journal of antimicrobial agents, 2022, Volume: 59, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Antigens, CD; beta-Lactamases; Cefotaxime; Escherichia coli; Escherichia coli Infections; Mice; Microbial Sensitivity Tests; Neoplasm Proteins; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

2022
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
    The Journal of antimicrobial chemotherapy, 2022, 08-25, Volume: 77, Issue:9

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2022
The prevalence of multiple drug resistance Escherichia coli and Klebsiella pneumoniae isolated from patients with urinary tract infections.
    Journal of clinical laboratory analysis, 2022, Volume: 36, Issue:9

    Topics: Ampicillin; Anti-Bacterial Agents; Aztreonam; Cefepime; Ceftazidime; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple; Escherichia coli; Escherichia coli Infections; Gentamicins; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Piperacillin; Prevalence; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections

2022
High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
    International journal of antimicrobial agents, 2022, Volume: 60, Issue:4

    Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Extraintestinal Pathogenic Escherichia coli; Gentamicins; Hospitals; Humans; Iron; Mozambique; Piperacillin; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination

2022
Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Escherichia coli clinical isolates.
    The Journal of antimicrobial chemotherapy, 2022, 10-28, Volume: 77, Issue:11

    Topics: Anti-Bacterial Agents; Ceftriaxone; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2022
Drug resistance characteristics and molecular typing of Escherichia coli isolates from neonates in class A tertiary hospitals: A multicentre study across China.
    The Journal of infection, 2022, Volume: 85, Issue:5

    Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Cefotaxime; Child; Ciprofloxacin; Doxycycline; Drug Resistance; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant, Newborn; Microbial Sensitivity Tests; Multilocus Sequence Typing; Piperacillin; Pregnancy; Tazobactam; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination

2022
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
    Scientific reports, 2023, 01-09, Volume: 13, Issue:1

    Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing

2023
Prevalence of Some Group A Beta-Lactamase Genes among Uropathogenic Escherichia coli isolated from Women with Cystitis.
    Cellular and molecular biology (Noisy-le-Grand, France), 2022, Sep-30, Volume: 68, Issue:10

    Topics: Anti-Bacterial Agents; beta-Lactamases; Cystitis; Escherichia coli Infections; Female; Humans; Piperacillin; Prevalence; Uropathogenic Escherichia coli

2022
Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.
    Infection, 2023, Volume: 51, Issue:6

    Topics: Adult; Ampicillin; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cohort Studies; Escherichia coli; Escherichia coli Infections; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolones; Retrospective Studies; Sulbactam

2023
Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla
    Nature communications, 2020, 10-01, Volume: 11, Issue:1

    Topics: Anti-Bacterial Agents; beta-Lactamases; Chromosomes, Bacterial; DNA Transposable Elements; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Gene Amplification; Gene Expression Regulation, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Piperacillin; Polymorphism, Restriction Fragment Length; RNA, Ribosomal, 16S; Tazobactam; Whole Genome Sequencing

2020
Plasmid-Mediated Colistin Resistance Gene mcr-1 in an Escherichia coli ST10 Bloodstream Isolate in the Sultanate of Oman.
    Microbial drug resistance (Larchmont, N.Y.), 2018, Volume: 24, Issue:3

    Topics: Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Colistin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Gene Expression; Humans; Membrane Proteins; Microbial Sensitivity Tests; Oman; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Protein Isoforms; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination

2018
Fungating groin mass in a woman with a history of follicular lymphoma.
    BMJ case reports, 2017, Aug-16, Volume: 2017

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Ceftriaxone; Cyclophosphamide; Diagnosis, Differential; Escherichia coli Infections; Female; Groin; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Penicillanic Acid; Piperacillin; Positron-Emission Tomography; Rituximab; Tazobactam; Tomography, X-Ray Computed; Vincristine

2017
Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018, Volume: 37, Issue:2

    Topics: Aged; Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Retrospective Studies; Tertiary Care Centers; Thienamycins; Treatment Outcome

2018
Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India.
    Infectious diseases (London, England), 2018, Volume: 50, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Hospitalization; Humans; India; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Young Adult

2018
Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Diagnostic microbiology and infectious disease, 2018, Volume: 91, Issue:1

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins

2018
Perioperative antibiotic prophylaxis in renal transplantation: a single-center comparison between two regimens and a brief survey among the Eurotransplant renal transplantation centers.
    World journal of urology, 2019, Volume: 37, Issue:5

    Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefazolin; Escherichia coli Infections; Europe; Female; Floxacillin; Humans; Kidney Transplantation; Male; Middle Aged; Perioperative Care; Piperacillin; Postoperative Complications; Retrospective Studies; Sepsis; Sex Factors; Sulbactam; Surgical Wound Infection; Surveys and Questionnaires; Urinary Tract Infections

2019
Intramedullary Antibiotic Delivery for Emphysematous Osteomyelitis of the Femur.
    Orthopedics, 2019, Jan-01, Volume: 42, Issue:1

    Topics: Anti-Bacterial Agents; Bone Cements; Bone Nails; Emphysema; Escherichia coli; Escherichia coli Infections; Female; Femur; Humans; Middle Aged; Osteomyelitis; Piperacillin; Tazobactam

2019
UPLC/MS/MS assay for the simultaneous determination of seven antibiotics in human serum-Application to pediatric studies.
    Journal of pharmaceutical and biomedical analysis, 2019, Sep-10, Volume: 174

    Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Blood Chemical Analysis; Calibration; Cefotaxime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Ciprofloxacin; Escherichia coli Infections; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Limit of Detection; Male; Meropenem; Metronidazole; Pediatrics; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry

2019
Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:5

    Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Female; Imipenem; Injections, Intramuscular; Injections, Intraperitoneal; Intraabdominal Infections; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Treatment Outcome

2013
The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:8

    Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam

2013
Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7

    Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cohort Studies; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Treatment Outcome; Urinary Tract Infections

2013
Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clindamycin; Diabetic Foot; Escherichia coli; Escherichia coli Infections; Gene Expression; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Multiplex Polymerase Chain Reaction; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Structural Homology, Protein; Structure-Activity Relationship

2013
In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 57, Issue:10

    Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Disease Models, Animal; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Mice; Microbial Sensitivity Tests; Nociceptive Pain; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections

2013
Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2014, Volume: 16, Issue:1

    Topics: Adult; Amikacin; beta-Lactamases; beta-Lactams; Cefoxitin; Ciprofloxacin; Drug Resistance, Bacterial; End Stage Liver Disease; Enterobacter cloacae; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Feces; Female; Humans; Imipenem; Klebsiella; Klebsiella Infections; Klebsiella pneumoniae; Liver Transplantation; Logistic Models; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Preoperative Period; Risk Factors; Severity of Illness Index

2014
Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Combinations; Escherichia coli; Escherichia coli Infections; Klebsiella Infections; Klebsiella pneumoniae; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis

2014
Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Microbial drug resistance (Larchmont, N.Y.), 2015, Volume: 21, Issue:2

    Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefepime; Cephalosporins; Child; Escherichia coli; Escherichia coli Infections; Febrile Neutropenia; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies

2015
Clinical Impact of Discordant Prescribing of Fluoroquinolones and Alternative Treatments in Escherichia coli Pyelonephritis.
    Journal of pharmacy practice, 2016, Volume: 29, Issue:5

    Topics: Adult; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli Infections; Female; Fluoroquinolones; Guidelines as Topic; Humans; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Treatment Outcome

2016
Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli.
    Journal of medical microbiology, 2015, Volume: 64, Issue:11

    Topics: Anti-Bacterial Agents; beta-Lactamases; Culture Media; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Penicillanic Acid; Piperacillin; Porins; Tazobactam

2015
Sub-Inhibitory Concentration of Piperacillin-Tazobactam May be Related to Virulence Properties of Filamentous Escherichia coli.
    Current microbiology, 2016, Volume: 72, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Biofilms; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Intraabdominal Infections; Locomotion; Metabolism; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Virulence

2016
Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Japan; Klebsiella Infections; Klebsiella oxytoca; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Penicillanic Acid; Piperacillin; Tazobactam

2015
Tubo-ovarian abscess in non sexually active adolescents.
    International journal of adolescent medicine and health, 2017, Apr-01, Volume: 29, Issue:2

    Topics: Abscess; Adult; Anti-Bacterial Agents; Diagnosis, Differential; Escherichia coli; Escherichia coli Infections; Female; Humans; Ovarian Diseases; Piperacillin; Sexual Abstinence; Treatment Outcome; Young Adult

2017
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2016, Volume: 49, Issue:4

    Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine

2016
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting.
    Journal of clinical microbiology, 2016, Volume: 54, Issue:12

    Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Cross Infection; Enterococcus faecium; Escherichia coli; Escherichia coli Infections; Genome, Bacterial; Gram-Positive Bacterial Infections; High-Throughput Nucleotide Sequencing; Humans; Infection Control; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Staphylococcal Infections; Vancomycin-Resistant Enterococci

2016
In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:12

    Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Colistin; Culture Media; Disease Models, Animal; Drug Administration Schedule; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tobramycin; Treatment Outcome

2016
Complicated acute appendicitis presenting as a rapidly progressive soft tissue infection of the abdominal wall: a case report.
    Journal of medical case reports, 2016, Dec-01, Volume: 10, Issue:1

    Topics: Abdominal Pain; Abdominal Wall; Anti-Bacterial Agents; Appendectomy; Appendicitis; Emphysema; Escherichia coli Infections; Female; Humans; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reoperation; Soft Tissue Infections; Tomography, X-Ray Computed; Treatment Outcome

2016
Detection of Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli with Current Automated Susceptibility Test Systems.
    Infection control and hospital epidemiology, 2017, Volume: 38, Issue:3

    Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2017
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Failure; Young Adult

2017
Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    International journal of antimicrobial agents, 2008, Volume: 32, Issue:4

    Topics: Anti-Bacterial Agents; Automation; beta-Lactamases; Deoxyribonucleases, Type II Site-Specific; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Polymerase Chain Reaction; Sequence Analysis, DNA; Tazobactam

2008
Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU.
    Intensive care medicine, 2009, Volume: 35, Issue:5

    Topics: beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Critical Care; Drug Resistance, Microbial; Drug Resistance, Multiple; Escherichia coli; Escherichia coli Infections; Female; Humans; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Length of Stay; Male; Medication Therapy Management; Microbial Sensitivity Tests; Middle Aged; Organizational Policy; Piperacillin

2009
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2010, Volume: 16, Issue:2

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors

2010
[Appendicitis in an HIV-positive South American immigrant].
    Enfermedades infecciosas y microbiologia clinica, 2010, Volume: 28, Issue:2

    Topics: Abdominal Abscess; Albendazole; Animals; Anthelmintics; Anti-HIV Agents; Appendectomy; Appendicitis; Ascariasis; Ascaris lumbricoides; Bacteroides fragilis; Bacteroides Infections; Combined Modality Therapy; Emigrants and Immigrants; Escherichia coli Infections; Female; HIV Infections; Humans; Immunocompromised Host; Intestinal Diseases, Parasitic; Jejunum; Paraguay; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult

2010
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic

2010
Protective effect of citropin 1.1 and tazobactam-piperacillin against oxidative damage and lethality in mice models of gram-negative sepsis.
    The Journal of surgical research, 2011, Volume: 171, Issue:2

    Topics: Amphibian Proteins; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Penicillanic Acid; Piperacillin; Tazobactam

2011
Successful pelvic abscess drainage by cecal biopsies in Crohn's disease.
    Gastrointestinal endoscopy, 2011, Volume: 73, Issue:1

    Topics: Abscess; Biopsy; Child; Colonoscopy; Crohn Disease; Drainage; Escherichia coli Infections; Humans; Ileum; Klebsiella Infections; Piperacillin; Prednisone

2011
In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
    The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:5

    Topics: Anti-Bacterial Agents; beta-Lactamases; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Microbial Viability; Mutant Proteins; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2011
PK-PD modeling of β-lactam antibiotics: in vitro or in vivo models?
    The Journal of antibiotics, 2011, Volume: 64, Issue:6

    Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Immunocompromised Host; Male; Models, Biological; Piperacillin; Rats; Rats, Wistar

2011
Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Escherichia coli Infections; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2012
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Jan-15, Volume: 54, Issue:2

    Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamase Inhibitors; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proportional Hazards Models; Prospective Studies; Spain

2012
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1

    Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh

2012
Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in Escherichia coli.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:2

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; DNA Replication; Escherichia coli; Escherichia coli Infections; Gene Dosage; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Point Mutation; RNA, Antisense

2012
First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Cephalosporins; Denmark; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Meropenem; Middle Aged; Mycoses; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins

2012
A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit.
    The Journal of surgical research, 2012, Volume: 176, Issue:2

    Topics: Anti-Bacterial Agents; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Surgical Wound Infection

2012
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2016, Volume: 49, Issue:3

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2016
Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11

    Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Case-Control Studies; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Regression Analysis; Risk Factors; Tazobactam

2012
International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2013, Volume: 32, Issue:8

    Topics: Anti-Bacterial Agents; Cluster Analysis; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Reference Standards; Reproducibility of Results

2013
Antiendotoxin activity of antimicrobial peptides and glycopeptides.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Colistin; Disease Models, Animal; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Injections, Intraperitoneal; Male; Penicillins; Piperacillin; Proteins; Random Allocation; Rats; Rats, Wistar; Shock, Septic; Teicoplanin; Vancomycin

2003
Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms.
    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2003, Volume: 36, Issue:3

    Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Taiwan

2003
Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock.
    Annals of surgery, 2004, Volume: 239, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Drug Synergism; Drug Therapy, Combination; Endotoxins; Escherichia coli; Escherichia coli Infections; Imipenem; Injections, Intraperitoneal; Insect Proteins; Lipopolysaccharides; Male; Piperacillin; Rats; Rats, Wistar; Shock, Septic

2004
Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock.
    Peptides, 2003, Volume: 24, Issue:11

    Topics: Animals; Antimicrobial Cationic Peptides; Cecum; Disease Models, Animal; Drug Therapy, Combination; Escherichia coli Infections; Ligation; Lipopolysaccharides; Male; Microbial Sensitivity Tests; Peptides; Peritonitis; Piperacillin; Proteins; Punctures; Rats; Rats, Wistar; Shock, Septic

2003
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    International journal of antimicrobial agents, 2004, Volume: 23, Issue:5

    Topics: Anti-Bacterial Agents; beta-Lactamases; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Mathematics; Models, Biological; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome

2004
Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:3

    Topics: Abdomen; Amino Acid Sequence; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cecum; Colony Count, Microbial; Endotoxins; Escherichia coli; Escherichia coli Infections; Injections, Intraperitoneal; Male; Microbial Sensitivity Tests; Penicillins; Peritonitis; Piperacillin; Rats; Rats, Wistar; Sepsis; Shock, Septic; Tumor Necrosis Factor-alpha

2004
Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock.
    Peptides, 2005, Volume: 26, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cecum; Drug Therapy, Combination; Endotoxins; Escherichia coli; Escherichia coli Infections; Imipenem; Injections, Intraperitoneal; Limulus Test; Lipopolysaccharides; Male; Piperacillin; Polymyxin B; Rats; Rats, Wistar; Shock, Septic; Time Factors; Tumor Necrosis Factor-alpha

2005
Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.
    Scandinavian journal of infectious diseases, 2005, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Denmark; Drug Resistance, Bacterial; Escherichia coli Infections; Female; Humans; Incidence; Male; Medical Records; Middle Aged; Netilmicin; Piperacillin; Retrospective Studies

2005
LL-37 protects rats against lethal sepsis caused by gram-negative bacteria.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Cecum; Disease Models, Animal; Endotoxins; Escherichia coli; Escherichia coli Infections; Gram-Negative Bacteria; Imipenem; Injections, Intraperitoneal; Male; Nitrites; Piperacillin; Polymyxin B; Random Allocation; Rats; Rats, Wistar; Serotyping; Shock, Septic; Tumor Necrosis Factor-alpha

2006
Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2006, Dec-01, Volume: 43, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cephalosporins; Cohort Studies; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination

2006
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole.
    Hawaii medical journal, 2007, Volume: 66, Issue:3

    Topics: Alcaligenes; Amphotericin B; Amputation, Surgical; Antifungal Agents; Cefazolin; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Drug Resistance, Multiple, Fungal; Escherichia coli Infections; Fatal Outcome; Fluconazole; Gangrene; Graft Rejection; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Leg; Leg Ulcer; Male; Middle Aged; Mucor; Mucormycosis; Penicillanic Acid; Phosphatidylcholines; Phosphatidylglycerols; Piperacillin; Postoperative Complications; Pyrimidines; Renal Dialysis; Reoperation; Sepsis; Skin Transplantation; Tazobactam; Triazoles; Voriconazole

2007
Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Singapore medical journal, 2007, Volume: 48, Issue:6

    Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Hospitals, Urban; Humans; India; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins

2007
Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
    Journal of medical microbiology, 2007, Volume: 56, Issue:Pt 11

    Topics: Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Blood; Colony Count, Microbial; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis

2007
[Replacement of third-generation cephalosporins by piperacillin-tazobactam decreases colonization of extended-spectrum beta-lactamases-producing intestinal Escherichia coli].
    Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:9

    Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Escherichia coli; Escherichia coli Infections; Female; Humans; Intestines; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies

2007
Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
    Critical care medicine, 2008, Volume: 36, Issue:1

    Topics: Animals; Anti-Infective Agents; Antimicrobial Cationic Peptides; Disease Models, Animal; Drug Therapy, Combination; Enterococcus faecalis; Escherichia coli; Escherichia coli Infections; Gram-Positive Bacterial Infections; Male; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Rats; Rats, Wistar; Shock, Septic; Tazobactam; Treatment Outcome

2008
Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: a retrospective study.
    BMC infectious diseases, 2008, May-17, Volume: 8

    Topics: Anti-Bacterial Agents; beta-Lactamases; Cohort Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; France; Humans; Incidence; Intensive Care Units; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Treatment Outcome

2008
Piperacillin treatment of urinary infections.
    The Medical journal of Australia, 1981, Jan-10, Volume: 1, Issue:1

    Topics: Adult; Aged; Enterobacter; Enterobacteriaceae Infections; Escherichia coli Infections; Female; Humans; Injections, Intravenous; Klebsiella Infections; Male; Middle Aged; Penicillins; Piperacillin; Proteus Infections; Pseudomonas Infections; Urinary Tract Infections

1981
Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:12

    Topics: Ampicillin; Animals; Anti-Bacterial Agents; Aztreonam; Cefazolin; Cefotaxime; Disease Models, Animal; Escherichia coli Infections; Male; Mice; Peritoneal Diseases; Piperacillin

1996
Efficacy of antibacterial drugs in mice with complex infection by Candida albicans and Escherichia coli.
    The Journal of antibiotics, 1999, Volume: 52, Issue:6

    Topics: Ampicillin; Animals; Anti-Bacterial Agents; Candida albicans; Candidiasis; Cefotaxime; Escherichia coli; Escherichia coli Infections; Female; Gentamicins; Kanamycin; Kidney; Mice; Mice, Inbred ICR; Minocycline; Piperacillin; Tetracycline

1999
Emergence of piperacillin/tazobactam-resistant Escherichia coli.
    Intensive care medicine, 2000, Volume: 26, Issue:10

    Topics: beta-Lactamase Inhibitors; Communicable Diseases, Emerging; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli Infections; France; Humans; Infection Control; Intensive Care Units; Patient Selection; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam

2000
Simulation of human serum pharmacokinetics of cefazolin, piperacillin, and BRL 42715 in rats and efficacy against experimental intraperitoneal infections.
    Antimicrobial agents and chemotherapy, 1992, Volume: 36, Issue:7

    Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Biological Availability; Cefazolin; Drug Therapy, Combination; Escherichia coli Infections; Humans; Infusions, Intravenous; Lactams; Male; Microbial Sensitivity Tests; Peritonitis; Piperacillin; Rats; Rats, Inbred Strains; Serratia Infections

1992
Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
    Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:5

    Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Escherichia coli; Escherichia coli Infections; Meningitis; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Rabbits; Tazobactam

1990
A new model of bacterial peritonitis in mice for evaluation of antibiotics. Effects of aspoxicillin and piperacillin.
    The Japanese journal of antibiotics, 1989, Volume: 42, Issue:4

    Topics: Amoxicillin; Ampicillin Resistance; Animals; Ascitic Fluid; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Male; Mice; Peritonitis; Piperacillin

1989
Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women.
    The American journal of medicine, 1985, Nov-29, Volume: 79, Issue:5B

    Topics: Acute Disease; Adolescent; Adult; Aged; Clavulanic Acid; Clavulanic Acids; Drug Combinations; Drug Evaluation; Escherichia coli Infections; Female; Humans; Middle Aged; Penicillins; Piperacillin; Pyelonephritis; Ticarcillin

1985